Tofacitinib for new-onset adult patients with anti-melanoma differentiation-associated 5 gene antibody positive dermatomyositis

Wang, Yanhua; Luo, Jing; Lv, Xiaohong; Li, Yuanyuan; An, Qi; Mo, Lingfei; Hu, Nan; Zhang, Jing; Wang, Jing; Tian, Juan; Pu, Dan; Hao, Zhiming

doi:10.1007/s10067-023-06567-y

Cited by 11 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-MDA5+ DM is one of the most complicated diseases with poor treatment response to GCs and immunosuppressive therapy. High mortality in this subset of patients with DM has been extensively reported in many cohorts [3,[27][28][29][30][31]. The present study showed that most fatalities occurred within the first half of the year of the disease and mainly occurred in the severe lymphopenia group.…”

Section: Discussionsupporting

confidence: 72%

Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti‐MDA5‐positive dermatomyositis

Jin

Yang

et al. 2023

J Intern Med

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 72%

Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti‐MDA5‐positive dermatomyositis

Jin

Yang

et al. 2023

J Intern Med

View full text Add to dashboard Cite

show abstract

“…There was no significant change in FVC, but there was improvement in DLCO at 6 months compared with baseline (p ¼ 0.009). 98 A prospective cohort of 52 patients with anti-MDA5-positive DM and mean disease duration of 6.5 months who were treated with tofacitinib showed clinical symptom improvement in 59.6% of patients. 99 A final case series of six patients with anti-MDA5positive DM and RP-ILD who failed triple therapy and addition of tofacitinib 10 mg daily is reported.…”

Section: Tofacitinibmentioning

confidence: 97%

Novel Therapeutic Approaches in Connective Tissue Disease-Associated Interstitial Lung Disease

Mulcaire-Jones,

Pugashetti,

Oldham

et al. 2024

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Connective tissue diseases (CTD) comprise a group of autoimmune diseases that can affect multiple organs in the body including the lungs. The most common form of pulmonary involvement is interstitial lung disease (ILD). CTD-associated ILD (CTD-ILD) can take one of several courses including nonprogressive, chronically progressive, or rapidly progressive. Chronically and rapidly progressive patterns are associated with increased mortality. Limited randomized controlled trial data are available for treatment of CTD-ILD, with most data coming from systemic sclerosis-related ILD. The current first-line treatment for all CTD-ILD is immunosuppression with consideration of antifibrotics, stem cell transplant, and lung transplant in progressive disease. In this article, we review data for ILD treatment options in systemic sclerosis, rheumatoid arthritis, myositis, and primary Sjögren's syndrome-related ILDs.

show abstract

Idiopathic Inflammatory Myositis

Yıldırım,

Santos,

Isenberg

2024

Neuroimmune Diseases

View full text Add to dashboard Cite

Tofacitinib for new-onset adult patients with anti-melanoma differentiation-associated 5 gene antibody positive dermatomyositis

Cited by 11 publications

References 34 publications

Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti‐MDA5‐positive dermatomyositis

Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti‐MDA5‐positive dermatomyositis

Novel Therapeutic Approaches in Connective Tissue Disease-Associated Interstitial Lung Disease

Idiopathic Inflammatory Myositis

Contact Info

Product

Resources

About